FGF23 and X-linked hypophosphatemia: We also provide guidance on medical management of XLH in children and adolescents with oral phosphate and active vitamin D analogs, known as “conventional treatment,” and with burosumab, a recombinant human IgG1 monoclonal antibody to FGF23.